

**Dennis J. Slamon, M.D., Ph.D.**

NAME SLAMON, Dennis J. M.D., Ph.D.	POSITION TITLE Professor of Medicine, UCLA
------------------------------------	--

EDUCATION (Begin with baccalaureate or other initial professional education, such as nursing, and include postdoc training.)

INSTITUTION AND LOCATION	DEGREE	YEAR CONFERRED	FIELD OF STUDY
Washington and Jefferson College, Washington, PA	B. S.	1970	Biology
Pritzker School of Medicine, University of Chicago, Illinois	M.D.	1975	(Honors)
	Ph.D.	1975	Medicine, Cell Biology

**TRAINING**

1975-1978 Intern and Resident, Department of Medicine, University of Chicago Hospitals and Clinics

1978-1979 Chief Resident, Department of Medicine, University of Chicago

1979-1981 Fellow, Division of Hematology-Oncology, UCLA School of Medicine

**BOARD CERTIFICATION**

1978 Board Certified in Internal Medicine

1982 Board Certified in Medical Oncology

**AWARDS AND SOCIETIES**

1970 Phi Sigma Award in Biology, Washington and Jefferson College

1976 Upjohn Award in Internal Medicine, University of Chicago Hospitals and Clinics

1986 Triton Biosciences, Inc. Research Directors Award for Outstanding Biomedical Research

1988 Western Society of Clinical Investigation - Outstanding Young Investigator Award

1988 Elected to American Society of Clinical Investigation (ASCI)

1988 Milken Family Medical Foundation Award in Cancer Research

1998 National Breast Cancer Coalition 1998 Special Recognition for Scientific Advances in Human Breast Cancer

1999 Americans for Medical Progress Education Foundation Albert B. Sabin Heroes of Science Award

1999 American Association of Cancer Researchers (AACR) 23rd Richard and Hinda Rosenthal Foundation Award

2000 University of California, San Diego/Salk Award for Translational Medicine

2001 Bristol Myers Squibb Millennium Award

2001 Brown-Hazen Award for Excellence in the Basic Sciences - Wadsworth Center, New York

2001 Alumni Award - Washington & Jefferson College

2002 Jeffrey A. Gottlieb Memorial Award - M.D. Anderson Cancer Center

2003 American Association of Cancer Research (AACR) 2<sup>nd</sup> Annual Dorothy P. Landon Award for Translational Cancer Research

**POSITIONS HELD**

1982-1984 Adjunct Assistant Professor of Medicine, Department of Medicine, UCLA School of Medicine

1984-1987 Assistant Professor of Medicine, Department of Medicine, UCLA School of Medicine

1988-1994 Associate Professor of Medicine, Department of Medicine, UCLA School of Medicine

1988-present Director of Clinical & Translational Research, Jonsson Comprehensive Cancer Center, UCLA School of Medicine

1991-present Chief, Division of Hematology-Oncology, Department of Medicine, UCLA School of Medicine

1993-present Professor of Medicine, Department of Medicine, UCLA School of Medicine

1994-present Executive Vice-Chair for Research, Department of Medicine, UCLA School of Medicine

**SELECTED PUBLICATIONS**

Chazin VR, Kaleko M, Miller AD, Slamon DJ: Transforming Mediated by the Human HER-2 Gene Independent of the Epidermal Growth Factor Receptor. *Oncogene* 7:1859-66, 1992.

Reissmann PT, Koga H, Takahashi R, Figlin RF, Holmes EC, Cordon-Cardo C, Slamon DJ: Inactivation of the Retinoblastoma Susceptibility Gene in Non-Small Cell Lung Cancer. *Oncogene* 8:1913-1919, 1993.

Press MF, Pike MC, Chazin VR, Hung G, Udove JA, Markowicz M, Danyluk J, Godolphin W, Sliwkowski M, Akita R, Paterson MC, Slamon DJ: HER-2/*neu* expression in node-negative breast cancer: Direct tissue quantitation by computerized image analysis and association of overexpression with increased risk of recurrent disease. *Cancer Res* 53:4960-4970, 1993.

Pietras RJ, Fendly B, Chazin V, Pegram M, Howell S, Slamon D: Monoclonal antibody to HER-2/*neu* receptor blocks DNA repair after cisplatin in human breast and ovarian carcinoma cells. *Oncogene* 9:(7) 1829-1838, 1994.

Press, MF, Gung, G, Godolphin W, Slamon DJ: Sensitivity of HER-2/*neu* antibodies in archival tissue samples: Potential source of error in immunohistochemical studies of oncogene expression. *Cancer Res* 54, 2771-2777, 1994.

Strohmeier T, Reese D, Press M, Ackermann R, Hartmann M, Slamon D: Expression of the c-KIT photo-oncogene and its Ligand Stem Cell Factor (SCF) in Normal and Malignant Human Testicular Tissue. *J of Urology* 153:511-515, 1995.

Pietras RJ, Arboleda J, Reese DM, Wongvipat N, Pegram MD, Ramos L, Gorman CM, Parker MG, Sliwkowski MX, Slamon DJ: HER-2 Tyrosine Kinase Pathway Targets Estrogen Receptor and Promotes Hormone-Independent Growth in Human Breast Cancer Cells. *Oncogene* 10:2435-2446, 1995.

- Silverstein MJ, Poller DN, Waisman JR, Colburn WJ, Barth A, Gierson ED, Lewinsky B, Gamagami P, Slamon DJ: Prognostic classification of breast ductal carcinoma-in-situ. *The Lancet* 345: 1154-1157, 1995.
- Levin WJ, Press MF, Gaynor RB, Sukhatme VP, Boone TC, Reissmann PT, Figlin RA, Holmes EC, Souza LM, Slamon DJ and the Lung Cancer Study Group. Expression patterns of immediate early transcription factors in human non-small cell lung cancer. *Oncogene* 11, 1261-1269, 1995.
- Pauletti G, Godolphin, W, Press MF, Slamon DJ: Detection and Quantitation of HER-2/neu Gene Amplification in Human Breast Cancer Archival Material Using Fluorescence *In Situ* Hybridization. *Oncogene* 13, 63-72, 1996.
- Casey G, Lopez, ME, Ramos JC, Plummer SJ, Arboleda JE., Shaughnessy M, Karlan B, Slamon D: DNA sequence analysis of exons 2 through 11 and immunohistochemical staining are required to detect all known p53 alterations in human malignancies. *Oncogene* 13:1971-1981, 1996.
- Pegram MD, Finn RS, Arzoo K, Beryt M, Pietras RJ, Slamon DJ: The Effect of HER-2/*neu* Overexpression on Chemotherapeutic Drug Sensitivity in Human Breast and Ovarian Cancer Cells. *Oncogene* 15, 537-547, 1997.
- Press MF, Bernstein L, Thomas PA., Meisner LF, Zhou J-Y, Robinson RA, Harris C, Slamon DJ, Phillips RN, Ross, JS, Flom KJ: HER-2/*neu* Gene amplification characterized by fluorescence in situ hybridization: Poor prognosis in node-negative breast carcinomas. *J Clin Oncol* 15 8:2894-2904, 1997.
- Wilson CA, Payton MN, Elliott GS, Buas FW, Cajulis EE, Grosshans D, Ramos L, Reese MD, Slamon DJ, Calzone FJ: Differential subcellular localization, expression and biological toxicity of BRCA1 and the splice variant BRCA1-11B. *Oncogene* 14 1-16, 1997.
- Pegram DM, Lipton A, Hayes D, Weber B, Baselga J, Tripathy D, Baly D, Baughman S, Twaddell T, Glaspy J, Slamon DJ: Phase II Study of Receptor Enhanced Chemosensitivity using Recombinant Humanized Anti-p185 HER-2/*neu* Monoclonal Antibody (rhuMab HER2) plus Cisplatin in Patients with HER-2/*neu*-Overexpressing Metastatic Breast Cancer Refractory to Chemotherapy Treatment. *J Clin Oncol* 16:8: 2659-2671 1998.
- Wilson CA, Ramos L, Villasenor R, Anders A, Press MF, Clarke K, Karlan BY, Chen J-J, Scully R, Livingston RH, Kuch RH, Kanter MH, Cohen S, Calzone FJ, Slamon DJ: Characterization of the human BRCA1 protein and its loss in high grade non-inherited breast cancers. *Nature Genetics* 21:236-240, 1998.
- Pegram M, Hsu S, Pietras RJ, Sliwkowski M, Beryt M, Coombs D, Baly D, Kabbinar K, Slamon DJ: Inhibitory Effects of Combinations of HER-2/*neu* Antibody and Chemotherapeutic Agents used for Treatment of Human Breast Cancers, *Oncogene* 18:2241-2251, 1999.
- Pietras RJ, Poen JC, Gallardo D, Wongvipat PN, Lee HJ, Slamon DJ: Monoclonal Antibody to HER-2/*neu* Receptor Modulates Repair of Radiation-Induced DNA Damage and Enhances Radiosensitivity of Human Breast Cancer Cells Overexpressing this Oncogene. *Cancer Research* 59:1347-1355, 1999.
- Cobleigh M., Vogel CL, Tripathy D, Robert NJ, Scholl S, Fehrenbacher L, Wolter JM, Paton V, Shak S, Leiberman G, Slamon DJ: Multinational Study of the Efficacy and Safety of Humanized Anti HER-2 Monoclonal Antibody in Women who have HER-2 Overexpressing Metastatic Breast Cancer that has Progressed after Chemotherapy for Metastatic Disease. *J Clin Oncol* 17(9): 2639-2648, 1999.
- Aguilar Z, Finn R, Kabbinar FF, Ramos LB, Pegram MD, Pietras RJ, Akita RW, Sliwkowski MX, Slamon DJ: Biologic effects of heregulin/*neu* differentiation factor on normal and malignant human breast and ovarian Epithelial Cells. *Oncogene* 18(44):6050-6062, 1999.
- Oh JJ, Grosshans DR, Wong SG, Slamon DJ: Identification of differentially expressed genes associated with HER-2/*neu* overexpression in human breast cancer cells. *Nucleic Acids Res* 27:4008-4017, 1999.
- Lopez A, Pegram M, Slamon DJ, Landaw E: A Model-based approach for assessing in vivo combination therapy interactions *PNAS* 96 (23)13023-13028, 1999.
- Pegram M, Slamon DJ: Biological Rationale for HER2/*neu* (c-erbB2) as a Target for Monoclonal Antibody Therapy *Seminars in Oncology* 27(5) Suppl 9 13-19, 2000.
- Pauletti G, Dandekar S, Rong H-M, Ramos L, Peng H-J MD, Seshadri R. Slamon DJ: Assessment of Methods for Tissue Based Detection of the HER-2/*neu* Alteration in Human Breast Cancer: A Direct Comparison of FISH and Immunohistochemistry. *J Clin Oncol* 18(21)3651-3664 2000.
- Pegram M, Lopez A, Konecny G, Slamon DJ: Trastuzumab and Chemotherapeutics: Drug Interactions and Synergies. *Seminars in Oncology* 27(6) Suppl. 11, 21-25, 2000.
- Paquette R, Dergham ST, Karpf E, Wang HJ, Slamon DJ, Souza L, Glaspy JA: Ex vivo expanded unselected peripheral blood: progenitor cells reduce posttransplantation neutropenia, thrombocytopenia, and anemia in patients with breast cancer. *Blood* 96:(7)2385-2390, 2000
- Vogel C, Cobleigh, MA, Tripathy D, Gutheil JC, Harris LN, Fehrenbacher L, Slamon D J, Murphy M, Novotny WF, Burchmore M, Shak S, Stewart SJ: First-Line, Single-Agent Herceptin® (trastuzumab) in Metastatic Breast Cancer: S Preliminary Report. *European Journal of Cancer* 37 S25-S29, 2001.
- Nabholtz J, Slamon DJ: New Adjuvant Strategies for Breast Cancer: Meeting the Challenge of Integrating Chemotherapy and Trastuzumab (Herceptin). *Seminars in Oncology* 28(1) Suppl. 3, 1-12, 2001.
- Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Pharm D, Bajamonde A, Fleming T, Eiermann W, Wolter J, Pegram M, Baselga J, Norton LA: Concurrent Administration of Anti-HER-2 Monoclonal Antibody and First Line Chemotherapy for HER2-Overexpressing Metastatic Breast Cancer: A Phase III, Multinational, Randomized, Controlled Trial. *New England Journal of Medicine* 344(11) 783-792, 2001.
- Poiesz BJ, Papsidero LD, Ehrlich G, Sherman M, Dube S, Poiesz M, Dillon K, Ruscetti FW, Slamon D, Fang C, Williams A, Duggan D, Glaser J, Gottlieb A, Goldberg J, Ratner L, Phillips P, Han T, Friedman-Kien A, Siegal F, Rai K, Sawitsky A, Sheremata LW, Dosik H, Cunningham C, Montagna R: Prevalence of HTLV-I-associated T-cell lymphoma. *Am J Hematol* 66(1):32-38, 2001.
- Konecny G, Untch M, Pihan A, Kimmig, R, Gropp M, Stieber P, Hepp H, Slamon D, Pegram M: Association of Urokinase-Type Plasminogen Activator and its Inhibitor with Disease Progression and Prognosis in Ovarian Cancer. *Clin Can Res* 7:1743-1749, 2001.
- Bergman, I, Barmada MA, Griffin JA, Slamon DJ: Treatment of Meningeal Breast Cancer Xenografts in the Rat Using an Anti-P185/HER2 Antibody. *Clin Ca Res* (7)2050-2056, 2001.
- Aguilar Z, Slamon DJ: The Transmembrane Heregulin Precursor Is Functionally Active. *J Biol Chem* 276(47):44099-44107, 2001.
- Fejzo SM, Slamon DJ: Frozen Tumor Tissue Microarray Technology for Analysis of Tumor RNA, DNA, and Proteins. *Am J Pathol* (159)1645-1650, 2001.
- Shawver LK, Slamon D, Ullrich A: Smart drugs: Tyrosine kinase inhibitors in cancer therapy. *Cancer Cell* (1)117-123, 2002.
- Oh JJ, West AR, Fishbein MC, Slamon DJ: A Candidate Tumor Suppressor Gene, H37, from the Human Lung Cancer Tumor Suppressor Locus 3p21.3. *Cancer Res* 62:3207-3213, 2002
- Konecny G, Slamon DJ: HER2 testing and correlation with efficacy of trastuzumab therapy. *Oncology* (Huntingt). 16(11):1576-1578, 2002.
- Vogel CL, Cobleigh MA, Tripathy D, Gutheil JC, Harris LN, Fehrenbacher L, Slamon DJ, Murphy M, Novony WF, Burchmore M, Shak S, Stewart SJ, Press M: Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER-2 overexpressing metastatic breast cancer. *J Clin Oncol*. 20(3):719-726, 2002.
- Paquette RL, Dergham ST, Karpf E, Wang HJ, Slamon DJ, Souza L, Glaspy JA: Culture conditions affect the ability of ex vivo expanded peripheral blood progenitor cells to accelerate hematopoietic recovery. *Exp Hematol*. (4)374-380, 2002.
- Press MF, Slamon DJ, Flom KJ Park J, Zhou JY, Bernstein L: Evaluation of HER-2/*neu* gene amplification and overexpression: comparison of frequently used assay methods in a molecularly characterized cohort of breast cancer specimens. *J Clin Oncol*. 20(14)3095-3105, 2002.
- Osoba D, Slamon DJ, Burchmore M, Murphy M: Effects on quality of life of combined trastuzumab and chemotherapy in women with metastatic breast cancer. *J Clin Oncol*. 20(14) 3106-3113.
- Namazie A, Alavi S, Olopade OI, Pauletti G, Aghamohammadi N, Aghamohammadi M, Gornbein JA, Calcatera TC, Slamon DJ, Wang MB, Srivatsan ES: Cyclin D1 amplification and p16(MTS1/CDK41) deletion correlate with poor prognosis in head and neck tumors. *Laryngoscope* 112(3):472-81, 2002.
- Buller RE, Shahin MS, Horowitz JA, Runnebaum IB, Mahavni V, Petruskas S, Kreienberg R, Karlan B, Slamon D, Pegram M: Long term follow-up of patients with recurrent ovarian cancer after Ad *p53* gene replacement with SCH 58500. *Cancer Gene Therapy* (9)567-572, 2002.
- Buller RE, Runnebaum IB, Karlan BY, Horowitz JA, Shahin M, Buekers T, Petruskas S, Kreienberg R, Slamon D, Pegram M: A phase I/II trial of rAd/*p53* (SCH 58500) gene replacement in recurrent ovarian cancer. *Cancer Gene Therapy* (9)553-566, 2002.

Konecny G, Pauletti G, Pegram M, Untch M, Dandekar S, Aguilar Z, Wilson C, Rong HM, Bauerfeind I, Felber M, Wang HJ, Beryt M, Seshadri R, Hepp H, Slamon DJ: Quantitative association between HER-2/neu and steroid hormone receptors in hormone receptor-positive primary breast cancer. J Natl Cancer Inst. 15;95(2):142-53, 2003.

Arboleda MJ, Lyons JF, Kabbinavar FF, Bray MR, Snow BE, Ayala R, Danino M, Karlan BY, Slamon DJ: Overexpression of AKT2/Protein Kinase Bbeta Leads to Up-Regulation of beta 1 Integrins, Increased Invasion, and Metastasis of Human Breast and Ovarian Cancer Cells. Cancer Res. 1;63(1):196-206, 2003.

## Curriculum Vitae

### **DENNIS J. SLAMON, M.D., Ph.D.**

**Birth Date** August 6, 1948  
New Castle, Pennsylvania

**Marital Status** Married

University of California, Los Angeles  
School of Medicine  
Department of Medicine  
Division of Hematology/Oncology  
10945 Le Conte Avenue  
Peter Van Ueberroth Building  
Los Angeles, California 90095-1678

#### **Education**

- 1970 B.A. Washington & Jefferson College, Washington, PA  
Major - Biology (Honors).
- 1975 M.D., University of Chicago, Pritzker School Medicine  
Chicago, IL
- 1975 Ph.D. in Cell Biology - Graduate degree research carried out in the laboratories  
of Drs. Winston Anderson and Werner Kirsten, Departments of Anatomy and Pathology

#### **Training**

- 1975-78 Intern and Resident, Department of Medicine, University of Chicago Hospitals  
and Clinics.
- 1978-79 Chief Resident, Department of Medicine, University of Chicago
- 1979-81 Fellow, Division of Hematology-Oncology, Department of Medicine,  
UCLA School of Medicine, Los Angeles

#### **Board Certification**

- 1978 Board Certified in Internal Medicine - September 1978
- 1982 Board Certified in Medical Oncology - November 1982

April, 2003

**Awards and Societies**

- 1970 Phi Sigma Award in Biology - Washington & Jefferson College.
- 1976 Upjohn Award in Internal Medicine - University of Chicago Hospitals and Clinics.
- 1986 Triton Biosciences, Inc. - Research Directors Award for Outstanding Biomedical Research.
- 1988 Western Society of Clinical Investigation - Outstanding Young Investigator Award.
- 1988 Elected to American Society of Clinical Investigation (ASCI).
- 1988 Milken Family Medical Foundation Award in Cancer Research.
- 1998 National Breast Cancer Coalition 1998 Special Recognition for Scientific Advances in Human Breast Cancer
- 1999 Americans for Medical Progress Education Foundation Albert B. Sabin Heroes of Science Award
- 1999 American Association of Cancer Researchers (AACR) 23rd Richard and Hinda Rosenthal Foundation Award
- 2000 University of California, San Diego/Salk Translational Award
- 2001 Bristol Myers Squibb Millennium Award
- 73 Brown-Hazen Award for Excellence in the Basic Sciences - Wadsworth Center, New York
- 2001 Alumni Award - Washington & Jefferson College
- 2002 Jeffrey A. Gottlieb Memorial Award - M.D. Anderson Cancer Center

**Memberships**

- American Association for the Advancement of Science
- American Society for Clinical Investigation
- American Association for Cancer Research
- American Society of Clinical Oncology

**Positions:**

1994-present	Executive Vice-Chair for Research, Department of Medicine, UCLA School of Medicine
1993-present	Professor of Medicine, Department of Medicine, UCLA School of Medicine
1992-1994	Vice-Chair for Finance, Department of Medicine, UCLA, School of Medicine
1991-present:	Chief, Division of Hematology-Oncology, Department of Medicine, UCLA School of Medicine.
1988-present:	Director of Clinical and Translational Research, Jonsson Comprehensive Cancer Center, UCLA School of Medicine.
1989-1991:	Associate Chief, Division of Hematology-Oncology, Department of Medicine, UCLA School of Medicine.
1987-1993:	Associate Professor of Medicine, Department of Medicine, UCLA School of Medicine.
1984-87:	Assistant Professor of Medicine, Department of Medicine, UCLA School of Medicine.
1982-84:	Adjunct Assistant Professor of Medicine, Department of Medicine, UCLA School of Medicine.
1991-present	Leadership Advisory Council, Jonsson Comprehensive Cancer Center
1991-present	Directors Administration Review Committee, Jonsson Comprehensive Cancer Center
1992-present	Breast Center Steering Committee, UCLA Medical Center
1992-present	Department of Medicine Executive Committee UCLA School of Medicine
1992-present	Director's Council, Jonsson Comprehensive Cancer Center
1993-1994	Search Committee, for Dean, UCLA School of Medicine.
1993	Task Force on New Technologies in Science, UCLA
1993	Dean's Advisory Council Jonsson Comprehensive Cancer Center
1993-1994	Chair, Search Committee for Chair of the Department of Pediatrics, UCLA School of Medicine
1994-present	Internal Scientific Review Committee, UCLA Medical Center
1994-present	Bowyer/Joint Oncology Center Steering Committee UCLA Medical Center
1994-1996	STAR (Specialty Training Academic Research) Program, Department of Medicine, UCLA School of Medicine.
1995-1996	Search Committee, Dean-School of Dentistry
1996-1997	Search Committee, Director, Revlon Breast Center
1996	Blue Ribbon Committee for Procedures for the Protection of Human Subjects at UCLA
1996	Master Planning I - Clinical and Applied Research Sub-Committee
1997	Master Planning II - Programs and Partnerships Committee
1998	Chair, Search Committee for Chief, Division of Pulmonary and Critical Care Medicine, Department of Medicine, UCLA School of Medicine

**Scientific Consultant to:**

Member of the President's Cancer Panel – 2000 to present  
U.S., Army Medical Research and Materiel Command, Breast Cancer Research Program –  
Integration Panel - 1994 to present  
National Breast Cancer Coalition, Washington D.C.  
National Institute for Health, Washington D.C.  
Panel Member National Institutes of Health - The Secretary's Conference. "To Establish a National  
Action Plan on Breast Cancer", Washington D.C.  
Oncology Advisory Board – Pharmacia  
Scientific Advisory Board – Sugen Inc.  
Scientific Advisory Board – ChromaVision  
Scientific Advisory Board – Canji Inc.

**PUBLICATIONS:**

1. Slamon DJ: Protective effect of the double-stranded polyribonucleotide, poly I:C, against rat erythroblastosis virus. *J Natl Cancer Inst* 5:851-863, 1973.
2. Slamon DJ: Hemolytic anemia induced by murine leukemia virus: Possible mechanisms of hemolysis and effects of an interferon inducer. *J Natl Cancer Inst* 55:329-338, 1975.
3. Muller R., Slamon DJ, Tremblay JM, Cline MJ, Verma IM: Differential expression of cellular oncogenes during pre and postnatal development of the mouse. *Nature* 299:660-664, 1982.
4. Muller R., Slamon DJ, Adamson ED, Tremblay JM, Muller D, Cline MJ, Verma I: Transcription of *c-onc* genes, *c-ras* and *c-fms* during mouse development.. *Mol Cell Biol* 3:1062-1069, 1983.
5. Slamon DJ, deKernion JB, Verma IM, Cline MJ: Expression of cellular oncogenes in human malignancies. *Science* 224:256-262, 1984.
6. Slamon DJ, Cline MJ: Expression of cellular oncogenes during embryonic and fetal development of the mouse. *Proc Natl Acad Sci USA* 81:7141-7145, 1984.
7. Slamon DJ, Shimotohno K, Cline MJ, Golde DW, Chen ISY: Identification of the putative transforming protein of the human T-cell leukemia viruses HTLV-I and HTLV-II. *Science* 226:61-65, 1984.
8. Slamon DJ: Oncogenes and human malignancy, 226-229. In: Cline, M.J. Moderator. *Oncogenes: Implications for the diagnosis and treatment of cancer.* *Ann Intern Med* 223-233, 1984.
9. Slamon DJ, Press MF, Murdock DC, Souza LM, Cline MJ, Golde DW, Gasson J.C, Chen ISY: Studies of the putative transforming protein of the human T-cell leukemia virus, Type I. *Science* 228:1427-1430, 1985.
10. Tanaka T, Slamon DJ, Cline MJ: Efficient generation of antibodies to oncoproteins using synthesized peptide antigens. *Proc Natl Acad Sci* 82:3400-3404, 1985.
11. Wachsman W, Slamon DJ, Shimotohno K, Golde DW, Chen ISY: The human T-cell leukemia virus *x* gene. *Cancer Res* 45:4550-4552, 1985.
12. Chen ISY, Slamon DJ, Rosenblatt JD, Shah N, Quan S.G., Wachsman W: The *x* gene is essential for HTLV replication. *Science* 229:54-58, 1985.
13. Shimotohno K, Miwa M, Slamon DJ, Chen ISY, Hishino, H, Tarano M, Fujino M, Sugimura T: Identification of new gene products coded from *x* regions of human T-cell leukemia viruses. *Proc Natl Acad Sci* 85:302-306, 1985.
14. Tanaka T, Slamon DJ, Battifora H, Cline MJ: Expression of p21 *ras* oncoproteins in human cancers. *Cancer Res* 46:1465-1470, 1986.
15. Rosenblatt J, Wachsman W, Shimotohno K, Slamon DJ, Chen ISY: The comparative molecular biology of HTLV-I and HTLV-II. *Proc. Imperial Japanese Cancer Research Fund M. Miwa et. al. (eds.)* 177-185, 1985.
16. Shah NP, Wachsman W, Souza L, Cann AJ, Slamon DJ, Chen ISY: Comparison of the trans-activation capabilities of the human T-cell leukemia virus type I and II *x* proteins. *Mol Cell Biol* 6:3626-3631, 1986.

17. Wachsman W, Cann A, William JL, Slamon DJ, Souza LM, Shah NP, Chen, ISY: HTLV x gene mutants exhibit novel transcriptional regulatory phenotypes. *Science* 235:674-677, 1986.
18. Slamon DJ, Boone TC, Seeger RC, Keith DE, Chazin V, Lee HC, Souza LM: Identification and characterization of the protein encoded by the human N-*myc* oncogene. *Science* 232:768-772, 1986
19. Chen ISY, Golde DW, Slamon DJ, Wachsman W: Comparative studies of HTLV-I and HTLV-II in: Leukemia 1985, UCLA Symposia, Volume 28, Gale RP, Golde DW, Eds. New York, Alan R. Liss, 1985.
20. Aboud M, Golde DW, Wachsman W, Rosenblatt JD, Cann AJ, Gaynor RB, Slamon DJ, Chen ISY: Biology and leukemogenicity of human T-cell leukemia viruses in human cancers. Eds. UCLA Symposium, Park City, Utah, Alan R. Liss, New York, 1986.
21. Chan JY, Slamon DJ, Nimer SD, Golde DW, Gasson JC: Regulation of expression of human granulocyte-macrophage colony-stimulating factor (GM-CSF). *Proc Natl Acad Sci* 83:8669-8673, 1986.
22. Slamon DJ, Boone TC, Murdock DC, Keith DE, Press MF, Larson RA, Souza LM: Studies of the human *c-myb* gene and its product in human acute leukemias. *Science* 233:347-351, 1986.
23. Tanaka T, Ida N, Shimoda H, Waki C, Slamon DJ, Cline MJ: Organ specific expression of *ras* oncoproteins during growth and development of the rat. *Mol Cell. Biochem* 70:97-104, 1986.
24. Fojo AT, Ueda K, Slamon DJ, Poplack DG, Gottesman MM, Pastan I: Expression of a multi-drug-resistance gene in human tumors and tissues. *Proc Natl Acad Sci USA* 84:265-269, 1987.
25. Tanaka T, Ida N, Waki C, Shimoda H, Slamon DJ, Cline MJ: Cell type-specific expression of *c-ras* gene products in the normal rat. *Mol Cell Biochem* 75:23-32, 1987.
26. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL: Human breast cancer: correlation of relapse and survival with amplification of the HER-2/*neu* oncogene. *Science* 235:177-182, 1987.
27. Slamon DJ: Proto-oncogenes and human cancers. *New Engl J Med* 317:955-957, 1987.
28. Tanaka T, Slamon DJ, Shimoda H, Waki C, Kawaguchi Y, Tanaka Y, Ida N: Expression of Ha-*ras* oncogene products in human neuroblastomas and the significant correlation with patient prognosis. *Cancer Res* 48:1030-1034, 1988.
29. Williams AE, Fang CY, Slamon DJ, Poiesz BJ, Sandler SG, Darr II, WF, Shulman G, McGowan EI, Douglas DK, Bowman RJ, Peetoom F, Kleinman SH, Lenes B, Prince HE, Dodd RY: Seroprevalence and epidemiological correlates of HTLV-I infection in American blood donors. *Science* 240:643-646, 1988.
30. Fang CT, Williams AE, Sandler SG, Slamon DJ, Poiesz BJ: Detection of antibodies to human T-lymphotropic virus type I (HTLV-I). *Transfusion* 28:179-183, 1988.
31. Norman JT, Boyle W, Bohman RE, Fischman G, Bowen JW, McDonough A, Slamon DJ, Fine LG: Patterns of mRNA expression during early cell growth differ in kidney epithelial cells destined to undergo compensatory hypertrophy versus regenerative hyperplasia. *Proc Natl Acad Sci USA*. 85:6768-6772, 1988.
32. Slamon DJ, Clark GM: Amplification of *c-erbB-2* and aggressive human breast tumors. *Science* 240:1796-1798, 1988.

33. Slamon DJ, Boyle WJ, Keith DE, Press MF, Golde DW, Souza LM: Subnuclear localization of the trans-activating protein of the human T-cell leukemia virus, type 1. *J Virol* 62:680-686, 1988.
34. McGuire WL, Johnson BE, Seeger RC, Slamon DJ: Oncogenes in clinical cancer. *Breast Cancer Research and Treatment* 10:217-227, 1988.
35. Wada RK, Seeger RC, Brodeur GM, Slamon DJ, Rayner SA, Tomayko MM, Reynold CP: Characterization of human neuroblastoma cell lines that lack *N-myc* gene amplification. *Prog Clin Biol Res* 271:57-69, 1988.
36. Seeger RC, Wada R, Brodeur GM, Moss TJ, Bjork RL, Sousa L, Slamon DJ: Expression of *N-myc* by neuroblastomas with one or multiple copies of the oncogene. *Prog Clin Biol Res* 271:41-49, 1988.
37. Rosenblatt JD, Cann AJ, Slamon DJ, Smalberg IS, Shah NP, Fuji J, Wachsmann W, Chen ISY: HTLV-II trans-activating is regulated by two overlapping nonstructural genes. *Science* 240:916-919, 1988.
38. Moss TJ, Law YM, Slamon DJ, Brodeur GM, Seeger RC: *N-myc* protein expression by neuroblastoma cells that have metastasized to bone marrow. *Prog Clin Biol Res* 271:91-101, 1988.
39. Glaser JB, Coleman P, Slamon DJ, Papsidero L, Ehrlich G, Poiesz BJ, Duggan D: Prevalence of HTLV-I and HIV infection among white parenteral drug abusers. *J. AIDS*, 1(4):415-417, 1988.
40. Triche TJ, Cavazzana AO, Navarro S, Reynolds CP, Slamon DJ, Seeger RE: *N-myc* protein expression in small round cell tumors. *Pro Clin Biol Res*. 271:475-485, 1988.
41. Cortes E, Detels R, Aboulafia D, Li XL, Moudgil T, Alam M, Bonecker C, Gonzaga A, Oyafuso L, Tondo M, Boite C, Hammershlak N, Capitani C, Slamon DJ, Ho DD: HIV-1, HIV-2 and HTLV-I infection in high risk groups in Brazil. *New Engl J Med*. 320:953-958, 1989.
42. Kastan MB, Slamon DJ, Civin CI: Expression of proto-oncogene *c-myc* in normal human hematopoietic cells. *Blood* 73:1444-1451, 1989.
43. Erlich GD, Davey FR, Kirshner JJ, Sninsky JJ, Kwok S, Slamon DJ, Kallish R., Poiesz BJ: A polyclonal CD4+ and CD8+ lymphocytosis in a patient doubly infected with HTLV-I and HIV-1: A clinical and molecular analysis. *Am J Hematol* 30:128-139, 1989.
44. Reissmann P, Simon MF, Lee WH, Slamon DJ: Studies of the retinoblastoma gene in human sarcomas. *Oncogene* 4:839-843, 1989.
45. Anderson D., Epstein JS, Lee TH, Larimore MD, Saxinger C, Kalyanaraman VS, Slamon DJ, Parks W, Poiesz BJ, Pierik LT, Lee H, Montagna R, Roche PA, Williams A, Blatner W: Serological confirmation of Human T-Lymphotropic Virus Type-I. Infection in healthy blood and plasma donors. *Blood* 74:2585-2591, 1989.
46. Slamon DJ, Press MF, Godolphin W, Ramos L, Haran P, Shek L, Stuart SG, Ullrich A: Studies of the *HER-2/neu* proto-oncogene in human breast cancer. *Cancer Cells* 7:371-384, 1989.
47. Chen IS., Slamon DJ: Diagnosis of human T-cell leukemia virus infection. HIV Detection by Genetic Engineering Methods. Steimer K, Luciw P, Eds. Marcel Dekker, Inc., New York, 275-292, 1989.
48. Erlich GD, Glaser JB, Abbot MA, Slamon DJ, Keith, D, Sliwkowski M, Brandis J, Keitelman E, Teramoto Y, Papsidero L, Simpkins H, Sninsky JJ, Poiesz, BJ: Detection of anti-HTLV-I *tax* antibodies in HTLV-I enzyme-linked immunosorbent assay-negative individuals. *Blood* 73: (3):1066-1072, 1989.

49. Slamon DJ, Godolphin W, Jones LA, Holt J., Wong SG, Keith DE, Levin WJ, Stuart SG, Udove J, Ullrich A, Press MF: Studies of the HER-2/*neu* proto-oncogene in human breast and ovarian cancer. *Science* 244:707-712, 1989.
50. Bacus S, Bacus J, Slamon DJ, Press M: HER-2/*neu* oncogene expression and DNA ploidy analysis in breast cancer. *Arch Pathol Lab Med* 114:164-169, 1990.
51. Natali P, Nicotra M, Bigotti A, Ventura I, Slamon DJ, Fendly B, Ullrich A: Expression of the p185 encoded by HER-2 oncogene in normal and transformed human tissues. *Int J Cancer* 45:457-461, 1990.
52. Read L, Keith D, Slamon DJ, Katzenellenbogen B: Hormonal modulation of HER-2/*neu* protooncogene messenger ribonucleic acid and p185 protein expression in human breast cancer cell lines. *Cancer Res* 50:3947-3951, 1990.
53. Press MF, Cordon-Cardo C, Slamon DJ: Expression of the HER-2/*neu* proto-oncogene in normal human adult and fetal tissues. *Oncogene* 5:953-962, 1990.
54. Lupu R, Colomer R, Zugmaier G, Shepard M, Slamon DJ, Lippman ME: Direct interaction of a ligand for the *erbB-2* oncogene product with the EGF receptor and p185*erbB-2*. *Science* 249:1552-1555, 1990.
55. Miller CW, Abdulkarim A, Tsay C, Slamon D, Ishizaki K, Toguchida J, Yamamuro T, Lampkin B, Koeffler PH: Frequency and structure of p53 rearrangements in human osteosarcoma. *Cancer Res* 50:7950-7954, 1990.
56. Chiba I, Takahashi T, Nau M, D'Amico D, Curiel DT, Mitsudomi T, Buchhagen DL, Carbone D, Piantadosi S, Koga H, Reissman PT, Slamon DJ, Holmes EC, Minna JD: (for the Lung Cancer Study Group). Mutations in the p53 gene are frequent in primary, resected non-small cell lung cancer. *Oncogene* 5:1603-1610, 1990.
57. Aboulafia DM, Koga H, Slamon DJ, Rosenblatt JD: A patient with progressive myelopathy and antibodies to HTLV-I and HIV in serum and cerebrospinal fluid. *Arch Neurol* 47:477-479, 1990.
58. Slamon DJ: Studies of the HER-2/*neu* proto-oncogene in human breast cancer. *Cancer Invest.* 8:(2)253, 1990.
59. Giovanella BC, Vardeman DM, Williams LJ, Taylor DJ, de Iplyi PD, Greeff PJ, Stehlin JS, Ullrich A, Cailleau R, Slamon D, Gary Jr., HE: Heterotransplantation of human breast carcinomas in nude mice: Correlation between successful heterotransplants, poor prognosis and amplification of the HER-2/*neu* oncogene. *Int J Cancer* 47:66-71, 1991.
60. Paterson MC, Dietrich KD, Danyluk J, Paterson AHG, Lees AW, Jamil N, Hanson J, Jenkins H, Krause BE, McBlain WA, Slamon DJ, Fourny RM: Correlation between *c-erbB-2* amplification and risk of recurrent disease in node-negative breast cancer. *Cancer Res* 51:556-567, 1991.
61. Strohmeyer T, Peter S, Hartmann M, Munemitsu S, Ackermann R, Ullrich A, Slamon DJ: Expression of the *hst-1* and *c-kit* proto-oncogenes in human testicular germ cell tumors. *Cancer Res* 51:1811-1816, 1991.
62. Tanaka T, Slamon DJ, Shimada H, Shimoda H, Fujisawa T, Ida N, Seeger RC: A Significant Association of Ha-ras p21 in Neuroblastoma Cells with Patient Prognosis. *Cancer* 68:1296-1302, 1991.
63. Strohmeyer T, Reissmann P, Cordon-Cardo C, Hartmann M, Ackermann R, Slamon D: Correlation between retinoblastoma gene expression and differentiation in human testicular tumors. *Proc Natl Acad Sci* 88:6662-6666, 1991.

64. Slamon DJ: Expression of the *nm23* gene and breast cancer prognosis. *J Nat Cancer Inst* 83:229-231, 1991.
65. Shepard HM, Lewis GD, Sarup JC, Fendly BM, Maneval D, Mordenti J, Figari I, Kotts CE, Palladino Jr., MA, Ullrich A, Slamon DJ: Monoclonal Antibody Therapy of Human Cancer: Taking the HER2 Protooncogene to the Clinic. *J Clin Immunol* 11:117-127, 1991.
66. Aboulafia DM, Mitsuyasu RT, Slamon DJ: Human T-Cell Leukemia Virus Infection in Non-Intravenous Drug Using HIV Seropositive Men in Los Angeles. *AIDS Res and Hum. Retr* 7:3, 333-336, 1991.
67. Tommasi S, Paradiso A, Mangia A, Barletta A, Simone G, Slamon DJ, de Lena M: Biological Correlation between HER-2/*neu* and Proliferative Activity in Human Breast Cancer. *Anti Cancer Research* 11:1395-1400, 1991.
68. Aboulafia DM, Bennett C, Koga H, Keith D, Slamon DJ: Human T-Cell Leukemia Virus Type I/II (HTLV-I/II) Serologic Testing: The Importance of Assaying for the Full Complement of Viral Antigens. *Viral. Immunol* 5:(2)105-111, 1992.
69. De Santes K, Slamon D, Anderson SK, Shepard M, Fendly B, Maneval D, Press O: Radiolabeled Antibody Targeting of the HER-2/*neu* Oncoprotein. *Cancer Res* 52:1916-1923, 1992.
70. Chazin VR, Kaleko M, Miller AD, Slamon DJ: Transformation Mediated by the Human HER-2 Gene Independent of the Epidermal Growth Factor Receptor. *Oncogene* 7:1859-66, 1992.
71. Leone A, Seeger, RC, Hong CM, Hu YY, Arboleda MJ, Brodeur GM, Stram D, Slamon DJ, Steeg PS: Evidence for *nm23* RNA overexpression, DNA amplification and mutation in aggressive childhood neuroblastomas. *Oncogene* 8:855-865, 1993.
72. Reissmann PT, Koga H, Takahashi R, Figlin RF, Holmes EC, Cordon-Cardo C, Slamon DJ: Inactivation of the Retinoblastoma Susceptibility Gene in Non-Small Cell Lung Cancer. *Oncogene* 8:1913-1919, 1993.
73. Press MF, Pike MC, Chazin VR, Hung G, Udove JA, Markowicz M, Danyluk J, Godolphin W, Sliwkowski M, Akita R, Paterson MC, Slamon DJ: HER-2/*neu* expression in node-negative breast cancer: Direct tissue quantitation by computerized image analysis and association of overexpression with increased risk of recurrent disease. *Cancer Res* 53:4960-4970, 1993.
74. Kimura E, Enns RE, Alcaraz JE, Arboleda J, Slamon DJ, Howell SB: Correlation of the survival of ovarian cancer patients with mRNA expression of the 60kD heat shock protein HSP-60. *J Clin Oncol* 11:(5)891-898, 1993.
75. Pietras RJ, Fendly B, Chazin V, Pegram M, Howell S, Slamon D: Antibody to HER-2/*neu* receptor blocks DNA repair after cisplatin in human breast and ovarian carcinoma cells. *Oncogene* 9:(7) 1829-1838, 1994
76. Press M., Hung G, Godolphin W, Slamon DJ: Sensitivity of HER-2/*neu* antibodies in archival tissue samples: Potential source of error in immunohistochemical studies of oncogene expression. *Cancer Res* 54:2771-2777, 1994.
77. Fleischhacker, M, Strohmeyer T, Imai Y, Slamon DJ, Koeffler HP: Mutations of the p53 gene are not detectable in human testicular tumors. *Modern Pathology* 7:(4)435-439, 1994.

78. Imai Y, Strohmeyer TG, Fleischhacker M, Slamon DJ, Koeffler HP: p53 Mutations and MDM-2 Amplification in Renal Cell Cancers. *Modern Pathology*, 7:(7)766-770, 1994.
79. Ronco L., Silverman SL, Wong SG, Slamon DJ, Park LS, Gasson JC: Identification of Conserved Amino Acids in the Human Granulocyte-Macrophage Colony-stimulating Factor Receptor  $\alpha$  Subunit Critical for Function. *J Biol Chem* 269:(1)277-283, 1994.
80. Karlan B., Jones J, Slamon DJ, Lagasse .D: Glucocorticoids stabilize HER-2/*neu* messenger RNA in human epithelial ovarian carcinoma cells. *Gynecol Oncol* 53:70-77, 1994.
81. Strohmeyer TG, Slamon DJ: Proto-oncogenes and tumor suppressor genes in human urological malignancies. *J of Urology* 151:1479-1497. 1994.
82. Press MF, Pike MC, Hung G, Zhou JY, Ma Y, George J, Dietz-Bank J, James W, Slamon DJ, Batsakis JG, El-Naggar AK: Amplification and Overexpression of HER-2/*neu* in Carcinomas of the Salivary Gland: Correlation with Poor Prognosis. *Cancer Res* 54:(21)5675-5682, 1994.
83. Levin WJ, Casey G, Ramos JC, Arboleda MJ, Reissmann PT, Slamon DJ: Tumor Suppressor and Immediate Early Transcription Factor Genes in Non-small Cell Lung Cancer. *Chest* 106:372S-376S, 1994.
84. Carbone DP, Mitsudomi T, Chiba I, Piantadosi S, Rusch V, Nowak, JA, McIntire D, Slamon D, Gazdar A, Minna J: p53 Immunostaining Positivity is Associated With Reduced Survival and is Imperfectly Correlated With Gene Mutations in Resected Non-small Cell Lung Cancer. A Preliminary Report of LCSG 871. *Chest* 106(6)Suppl:377S-381S, Dec 1994.
85. Strohmeyer T, Reese D, Press M, Ackermann R, Hartmann M, Slamon D: Expression of the c-KIT proto-oncogene and its Ligand Stem Cell Factor (SCF) in Normal and Malignant Human Testicular Tissue. *J of Urology* 153:511-515, Feb 1995.
86. Yates KE, Lynch MR, Wong SG, Slamon DJ, Gasson JC: Human c-FES is a Nuclear Tyrosine Kinase. *Oncogene* 10:1230-1242, 1995.
87. Pietras RJ, Arboleda J, Reese DM, Wongvipat N, Pegram M.D, Ramos L., Gorman CM, Parker MG, Sliwkowski, Slamon DJ: HER-2 Tyrosine Kinase pathway targets estrogen receptor and promotes hormone-independent growth in human breast cancer cells. *Oncogene* 10:2435-2446, 1995.
88. Levin WJ, Press MF, Gaynor RB, Sukhatme V., Boone TC, Reissmann PT, Figlin RA, Holmes EC, Souza LM, Slamon DJ and the Lung Cancer Study Group: Expression patterns of immediate early transcription factors in human non-small cell lung cancer. *Oncogene* 11:1261-1269, 1995.
89. Silverstein MJ, Poller DN, Waisman JR, Colburn WJ, Barth A, Gierson E, Lewinsky BS, Gamagami P, Slamon DJ: Ductal Carcinoma in Situ of the Breast: A Proposal for a Morphologic Classification based on High Nuclear Grade and Comedo Type Necrosis. *The Lancet* 345:1154-1157, 1995
90. Kotts CE, Su FM, Leddy C, Dodd T, Scates S, Shalaby MR, Wirth CM, Giltinan D, Schroff RW, Fritzberg AR, Shepard HM, Slamon DJ, Hutchins BM:  $^{186}\text{Re}$ -Labeled Antibodies to p185<sup>HER2</sup> as HER2-Targeted Radioimmunopharmaceutical Agents: Comparison of Physical and Biological Characteristics with  $^{125}\text{I}$  and  $^{131}\text{I}$ -Labeled Counterparts. *Cancer Biotherapy and Radiopharmaceuticals* 11(2):133-144, 1996.
91. Li B, Ouyang B, Pan H, Reissmann PT, Slamon DJ, Arceci R, Lu L, Dai W. Prk, a cytokine-inducible human protein serine/threonine kinase whose expression appears to be down-regulated in lung carcinomas *J Biol Chem* 271(32):19402-19408, 1996.

92. Pauletti G, Godolphin W, Press MF, Slamon DJ: Detection and Quantitation of HER-2/neu Gene Amplification in Human Breast Cancer Archival Material Using Fluorescence *In Situ* Hybridization, *Oncogene* 13:63-72, 1996.
93. Casey G, Lopez ME, Ramos JC, Plummer SJ, Arboleda JE, Shaughnessy M, Karlan B, Slamon D: DNA sequence analysis of exons 2 through 11 and immunohistochemical staining are required to detect all known p53 alterations in human malignancies, *Oncogene* 13:1971-1981, 1996.
94. Reese DM, Slamon DJ: HER-2/neu Signal Transduction in Human Breast and Ovarian Cancer. *Stem Cells*, 15:1-8, 1997.
95. Pegram MD, Finn R., Arzoo K, Beryt M, Pietras RJ, Slamon D.J: The Effect of HER-2/neu Overexpression on Chemotherapeutic Drug Sensitivity in Human Breast and Ovarian Cancer Cells. *Oncogene* 15:537-547, 1997.
96. Press MF, Bernstein L, Thomas PA, Meisner LF, Zhou J-Y, Robinson RA, Harris C, Slamon DJ, Phillips RN, Ross JS, Flom KJ: HER-2/neu Gene amplification characterized by fluorescence in situ hybridization: Poor prognosis in node-negative breast carcinomas. *J Clin Oncol* (15)8:2894-2904, 1997.
97. Wilson CA, Payton MN, Elliott GS, Buaas FW, Cajulis EE, Grosshans D, Ramos L, Reese MD, Slamon DJ, Calzone FJ: Differential subcellular localization, expression and biological toxicity of BRCA1 and the splice variant BRCA1- 11B. *Oncogene* 14:1-16, 1997.
98. Pegram MD, Lipton A, Hayes D, Weber B, Baselga J, Tripathy D, Baly D, Baughman S, Twaddell T, Glaspy J, Slamon DJ: Phase II study of receptor enhanced chemosensitivity using recombinant humanized anti-p185 HER-2/neu monoclonal antibody (rhMAB HER2) plus cisplatin in patients with HER-2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment. *J Clin Oncol* 16:(8)2659-2671, 1998.
99. Paquette RL, Pegram MD, Finn RS, Maneval DA Slamon DJ: Remission of human breast cancer xenografts on therapy with humanized monoclonal antibody to HER-2 receptor and DNA-reactive drugs. *Oncogene* 17(17):2223-2249, 1998.
100. Paquette RL, Gonzales E, Yoshimura R, Tran L, Choi R, Baldwin G, Slamon DJ, Glaspy J: Ex vivo expansion and differentiation of unselected peripheral blood progenitor cells in serum-free media. *J Hematother* 7(6):481-491, 1998.
101. Pegram MD, Pauletti G, Slamon DJ: HER-2/neu as a predictive marker of response to breast cancer therapy. *Breast Cancer Res Treat.* 52(1-3):65-77, Review, 1998.
102. Bischoff JR, Anderson L, Zhu Y, Mossie K, Ng L, Souza B, Schryver B, Flanagan P, Clairvoyant F, Ginther C, Chan CS, Novotny M, Slamon DJ, Plowman GD: A homologue of *Drosophila aurora* kinase is oncogenic and amplified in human colorectal cancers. *EMBO J.* Jun 1;17(11):3052-65, 1998.
103. Challita-Eid PM, Penichet ML, Shin SU, Poles T, Mosammaparast N, Mahmood K, Slamon DJ, Morrison SL, Rosenblatt JD: A B7.1-antibody fusion protein retains antibody specificity and ability to activate via the T cell costimulatory pathway. *J Immunol* 160(7):3419-26, Apr 1, 1998.
104. Pietras JR. Pegram MD, Finn RS, Maneval DA, Slamon DJ: Remission of Human breast cancer xenografts on therapy with humanized monoclonal antibody to HER-2 receptor and DNA-reactive drugs. *Oncogene* 17:2235-2249, 1998.

105. Wilson CA, Ramos L, Villasenor R, Anders A, Press MF, Clarke K, Karlan BY, Chen J-J, Scully R., Livingston RH, Kuch RH, Kanter MH, Cohen S, Calzone FJ, Slamon DJ: Localization of the human BRCA1 protein and its loss in high grade non-inherited breast cancers. *Nature Genetics*\_ 21:236-240, 1999.
106. Pegram M, Hsu S, Pietras RJ, Sliwkowski M, Beryt M, Coombs D, Baly D, Kabbinavar K, Slamon DJ: Inhibitory Effects of Combinations of HER-2/*neu* Antibody and Chemotherapeutic agents used for Treatment of Human Breast Cancers, *Oncogene* 18:2241-2251, 1999.
107. Pietras RJ, Poen JC, Gallardo D, Wongvipat PN, Lee HJ, Slamon DJ: Monoclonal Antibody to HER-2/*neu* Receptor Modulates Repair of Radiation-Induced DNA Damage and Enhances Radiosensitivity of Human Breast Cancer Cells Overexpressing this Oncogene. *Cancer Res* 59:1347-1355, 1999.
108. Pegram M, Slamon DJ: Combination Therapy With Trastuzumab (Herceptin) and Cisplatin for Chemoresistant Metastatic Breast Cancer: Evidence for Receptor-Enhanced Chemosensitivity. *Semin Oncol* 26(4): Suppl. 12, 89-95 (August) 1999.
109. Cobleigh MA, Vogel CL, Tripathy D, Robert NJ, Scholl S, Fehrenbacher L, Wolter JM, Paton V, Shak S, Leiberman G, Slamon DJ: Multinational Study of the Efficacy and Safety of Humanized Anti HER-2 Monoclonal Antibody in Women who have HER-2 Overexpressing Metastatic Breast Cancer that has Progressed after Chemotherapy for Metastatic Disease. *J Clin Oncol* 17(9):2639-2648, 1999.
110. Oh JJ, Grosshans DR, Wong SG, Slamon DJ: Identification of differentially expressed genes associated with HER-2/*neu* overexpression in human breast cancer cells, *Nucleic Acids Res* 27:4008-4017, 1999.
111. Aguilar Z, Akita RW, Finn R, Ramos LB, Pegram MD, Kabbinavar FF, Pietras RJ, Pisacane P, Sliwkowski MX, Slamon DJ: Biologic effects of heregulin/*neu* differentiation factor on normal and malignant human breast and ovarian Epithelial Cells. *Oncogene* 18:(44):6050-6062, 1999.
112. Lopez A, Pegram M, Slamon D.J, Landaw E: A Model-based approach for assessing in vivo combination therapy interactions. *PNAS* 96(23):13023-13028, 1999.
113. Reissman PT, Koga H, Figlin RA, Holmes EC, Slamon DJ, The Lung Cancer Study Group: Amplification and overexpression of the cyclin D1 and epidermal growth factor receptor genes in non-small-cell lung cancer. *J. Cancer Res Clin Oncol* (125):61-70, 1999.
114. Landgraf R, Pegram M, Slamon DJ, Eisenberg D: Cytotoxicity and specificity of directed toxins composed of diphtheria toxin and the EGF-like domain of heregulin beta1. PMID: 9485477; UI: 98153210, 1999.
115. Strawn LM, Kabbinavar F, Schwartz DP, Mann E, Shawver LK, Slamon DJ, Cherrington JM: Effects of SU101 in combination with cytotoxic agents on the growth of subcutaneous tumor xenografts. *Clin Cancer Res* 6(7):2931-2940, 2000.
116. Pegram M, Slamon DJ: Biological Rationale for HER2/*neu* (c-erbB2) as a Target for Monoclonal Antibody Therapy. *Semin Oncol* 27(5): Suppl 9:13-19 2000.
117. Pauletti G, Dandekar S, Rong H-M, Ramos L, Peng H-J MD, Seshadri R, Slamon DJ: Assessment of methods for tissue-based detection of the HER-2/*neu* alteration in human breast cancer: a direct comparison of fluorescence in situ hybridization and immunohistochemistry. *J Clin Oncol* 18(21) 3651-3664, 2000.

118. Pegram M, Lopez A, Konecny G, Slamon DJ: Trastuzumab and Chemotherapeutics: Drug Interactions and Synergies. *Semin Oncol* 27(6): Suppl 11:21-25, 2000.
119. Paquette R, Dergham ST, Karpf E, Wang HJ, Slamon DJ, Souza L, Glaspy JA: Ex vivo expanded unselected peripheral blood: progenitor cells reduce posttransplantation neutropenia, thrombocytopenia, and anemia in patients with breast cancer. *Blood* 96:(7)2385-2390, 2000.
120. Nabholz J, Slamon DJ: New Adjuvant Strategies for Breast Cancer: Meeting the Challenge of Integrating Chemotherapy and Trastuzumab (Herceptin). *Semin Oncol* 28(1): Suppl 3:1-12, February 2001.
121. Slamon DJ, Pegram M: Rationale for Trastuzumab (Herceptin) in Adjuvant Breast Cancer Trials. *Semin Oncol* 28(1): Suppl 3:13-19, February, 2001.
122. Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Pharm D, Bajamonde A, Fleming T, Eiermann W, Wolter J, Pegram M, Baselga J, Norton LA: Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that over expresses HER2. *N Engl J Med* 344(11):783-792, 2001.
123. Poiesz BJ, Papsidero LD, Ehrlich G, Sherman M, Dube S, Poiesz M, Dillon K, Ruscetti FW, Slamon D, Fang C, Williams A, Duggan D, Glaser J, Gottlieb A, Goldberg J, Ratner L, Phillips P, Han T, Friedman-Kien A, Siegal F, Rai K, Sawitsky A, Sheremata LW, Dosik H, Cunningham C, Montagna R: Prevalence of HTLV-I-associated T-cell lymphoma. *Am J Hematol* 66(1):32-38, 2001.
124. Konecny G, Untch M, Pihan A, Kimmig, R, Gropp M, Stieber P, Hepp H, Slamon D, Pegram M: Association of Urokinase-Type Plasminogen Activator and its Inhibitor with Disease Progression and Prognosis in Ovarian Cancer. *Clin Can Res* 7:1743-1749, 2001.
125. Bergman, I, Barmada MA, Griffin JA, Slamon DJ: Treatment of Meningeal Breast Cancer Xenografts in the Rat Using an Anti-P185/HER2 Antibody. *Clin Ca Res* (7)2050-2056, 2001.
126. Aguilar Z, Slamon DJ: The Transmembrane Heregulin Precursor Is Functionally Active. *J Biol Chem* 276(47):44099-44107, 2001.
127. Fejzo SM, Slamon DJ: Frozen Tumor Tissue Microarray Technology for Analysis of Tumor RNA, DNA, and Proteins. *Am J Pathol* (159)1645-1650, 2001.
128. Chan KC, Knox WF, Gandhi A, Slamon DJ, Potten CS, Bundred NJ: Blockade of growth factor receptors in ductal carcinoma in situ inhibits epithelial proliferation. *Br J Surg*. 88(3):412-418, 2001.
129. Shawver LK, Slamon D, Ullrich A: Smart drugs: Tyrosine kinase inhibitors in cancer therapy. *Cancer Cell* (1)117-123, 2002.
130. Oh JJ, West AR, Fishbein MC, Slamon DJ: A Candidate Tumor Suppressor Gene, *H37*, from the Human Lung Cancer Tumor Suppressor Locus 3p21.3. *Cancer Res* 62:3207-3213, 2002.
131. Konecny G, Slamon DJ: HER2 testing and correlation with efficacy of trastuzumab therapy. *Oncology (Huntingt)*. 16(11):1576-1578, 2002.
132. Vogel CL, Cobleigh MA, Tripathy D, Gutheil JC, Harris LN, Fehrenbacher L, Slamon DJ, Murphy M, Novotny WF, Burchmore M, Shak S, Stewart SJ, Press M: Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER-2 overexpressing metastatic breast cancer. *J Clin Oncol*. 20(3):719-726, 2002.

133. Paquette RL, Dergham ST, Karpf E, Wang HJ, Slamon DJ, Souza L, Glaspy JA: Culture conditions affect the ability of ex vivo expanded peripheral blood progenitor cells to accelerate hematopoietic recovery. *Exp Hematol.* (4)374-380, 2002.
134. Press MF, Slamon DJ, Flom KJ, Park J, Zhou JY, Bernstein L: Evaluation of HER-2/neu gene amplification and overexpression: comparison of frequently used assay methods in a molecularly characterized cohort of breast cancer specimens. *J Clin Oncol.* 20(14)3095-3105, 2002.
135. Osoba D, Slamon DJ, Burchmore M, Murphy M: Effects on quality of life of combined trastuzumab and chemotherapy in women with metastatic breast cancer. *J Clin Oncol.* 20(14) 3106-3113, 2002.
136. Namazie A, Alavi S, Olopade OI, Pauletti G, Aghamohammadi N, Aghamohammadi M, Gornbein JA, Calcaterra TC, Slamon DJ, Wang MB, Srivatsan ES: Cyclin D1 amplification and p16(MTS1/CDK41) deletion correlate with poor prognosis in head and neck tumors. *Laryngoscope* 112(3):472-81, 2002.
137. Buller RE, Shahin MS, Horowitz JA, Runnebaum IB, Mahavni V, Petrauskas S, Kreienberg R, Karlan B, Slamon D, Pegram M: Long term follow-up of patients with recurrent ovarian cancer after Ad *p53* gene replacement with SCH 58500. *Cancer Gene Therapy* (9)567-572, 2002.
138. Buller RE, Runnebaum IB, Karlan BY, Horowitz JA, Shahin M, Buekers T, Petrauskas S, Kreienberg R, Slamon D, Pegram M: A phase I/II trial of rAd/*p53* (SCH 58500) gene replacement in recurrent ovarian cancer. *Cancer Gene Therapy* (9)553-566, 2002.
139. Konecny G, Pauletti G, Pegram M, Untch M, Dandekar S, Aguilar Z, Wilson C, Rong HM, Bauerfeind I, Felber M, Wang HJ, Beryt M, Seshadri R, Hepp H, Slamon DJ: Quantitative association between HER-2/neu and steroid hormone receptors in hormone receptor-positive primary breast cancer. *J Natl Cancer Inst.* 15;95(2):142-53, 2003.
140. Arboleda MJ, Lyons JF, Kabbinavar FF, Bray MR, Snow BE, Ayala R, Danino M, Karlan BY, Slamon DJ: Overexpression of AKT2/Protein Kinase Bbeta Leads to Up-Regulation of beta 1 Integrins, Increased Invasion, and Metastasis of Human Breast and Ovarian Cancer Cells. *Cancer Res.* 1;63(1):196-206, 2003.

## **RESEARCH PAPERS - NON PEER REVIEW JOURNALS**

Rosenblatt, J., Wachsman, W, Shimotohno K, Slamon DJ, Chen ISY: The comparative molecular biology of HTLV-I and HTLV-II. Proc. Imperial Japanese Cancer Research Fund M. Miwa et al. (eds.) 177-185, 1985.

Chen ISY, Golde D, Slamon DJ, Wachsman W: Comparative studies of HTLV-I and HTLV-II in: Leukemia 1985, UCLA Symposia, Volume 28, Gale, R.P, Golde DW, Eds. New York, Alan R. Liss, 1985.

Aboud M, Golde DW, Wachsman W, Rosenblatt JD, Cann AJ, Gaynor RB, Slamon DJ, Chen ISY: Biology and leukemogenicity of human T-cell leukemia viruses in human cancers. Eds. UCLA Symposium, Park City, Utah, Alan R. Liss, New York, 1986.

Slamon, DJ, Chen ISY: RNA viruses and human cancer. Infectious Disease Newsletter 5:28-30, 1986

## **BOOK CHAPTERS**

1. Chen ISY, Slamon DJ: Diagnosis of human T-cell leukemia virus infection. HIV Detection by Genetic Engineering Methods. Steimer K, Luciw P, Eds. Marcel Dekker, Inc., New York, 275-292, 1989.
2. Park JW, Stagg R, Lewis G.D, Carter P, Maneval D., Slamon DJ, Jaffe H, Shepard HM: Anti-p185HER2 monoclonal antibodies: Biological properties and potential for immunotherapy. Genes, Oncogenes, and Hormones: Advances in Cellular and Molecular Biology of Breast Cancer. Dickson RB, Lippman ME, Eds. Kluwer Academic Publishers, Boston. 193-211, 1991.

## **EDITORIALS, LETTERS TO THE EDITOR, WRITINGS FOR POPULAR PRESS**

1. Slamon DJ: Cancer biology, Editorial overview. Current Opinion in Oncology 4:124-126, 1992.
2. Hawkins RA, Hoh C, Dahlbom M, Choi Y, Glaspy J, Tse N, Slamon D, Chen B, Messa C, Maddahi J, Phelps ME: PET Cancer Evaluations with FDG. J Nuclear Med 32:1555-1558, 1992.
3. Wilson CA, Payton MN, Pekar SK, Zhang K, Pacifici RE, Gudas JL, Thukral S, Calzone FJ, Reese DM, Slamon D: BRCA1 protein products: antibody specificity Nat Genet 1996 Jul;13(3):264-5.